April 2nd 2024
The company plans to announce full market availability of the RenaFlex ureteroscope system at a later date.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Uro Pipeline: FDA committee votes in favor of nocturia treatment approval
November 1st 2016Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Hydroxycitrate may have utility in treating stones
October 1st 2016A new laboratory study suggests that a widely available nutritional supplement has potential to become a new treatment for the wide majority of kidney stones. Clinical research is still pending, however, and there are important caveats about the findings.
Basic Science Research: Trimodal therapy shows promise in oligometastatic PCa
July 1st 2016Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
Shock wave lithotripsy: Down, but not out
March 1st 2016Once considered a primary option for kidney stone treatment, shock wave lithotripsy appears to be losing traction. Many urologists say its outcomes aren’t as reliable as those from ureteroscopy. But others say it remains an option that works well with proper patient selection and technique and offers what ureteroscopy doesn’t: a noninvasive option.
Smoking associated with greater risk of urolithiasis
February 1st 2016Two-thirds of patients attending a urology clinic for the management of urolithiasis failed to meet physical activity guidelines. In addition, patients with recent symptomatic urolithiasis were significantly more likely to be current smokers than those without recent symptomatic urolithiasis, according to a recent study.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Non-adherence to stone meds raises hospitalization risk
December 1st 2015When it comes to urinary stone disease, it appears that prescribers know what they’re doing. According to a study presented at the World Congress of Endourology and SWL in London, non-adherence to kidney stone medications led to a significant increase in adverse health outcomes.
Single-use ureteroscope yields high-quality images
December 1st 2015Findings from preclinical studies evaluating the performance of an investigational single-use digital flexible ureteroscope (Lithovue, Boston Scientific) support it as a viable alternative to current non-disposable flexible digital and fiberoptic ureteroscopes, said Brian H. Eisner, MD, at the World Congress of Endourology and SWL in London.
Breaking new ground (and kidney stones) with ultrasound
November 1st 2015Novel ultrasound-based techniques for propelling and breaking kidney stones could soon join ESWL and URS in the urologist’s treatment armamentarium. In this interview, Michael Bailey, PhD, discusses how these technologies work, what they’re capable of, and where they are in development.
Product Update: HIFU cleared, compact catheter launched
November 1st 2015Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.